We have launched a new study in China to establish introducing bradykinesia as a feature being measured by LID-Monitor.
Parkinson’s is the second most common neurodegenerative disorder and is characterised by bradykinesia – a slowness in carrying out movements.
Bradykinesia is often unpredictable for people with Parkinson’s – one moment they can move easily, while in the next they may struggle to initiate movements and see a general slowness in their physical actions.
Levodopa is the medication most commonly given to control the movement symptoms of Parkinson’s and alleviate bradykinesia.
‘On’ time is when levodopa is working well, and symptoms are controlled. ‘Off’ time is when levodopa is no longer working well and symptoms such as tremor, rigidity and slow movement re-emerge.
LID-Monitor is a wearable device that monitors patients’ side-effects to medication prescribed for Parkinson’s over a 24-hour period. The LID-Monitor currently monitors a side-effect of levodopa called ‘dyskinesia’.
Our new study, with Dr Sheng-Di Chen at the Department of Neurology & Institute of Neurology in Rui Jin, aims to measure the data to offer extra functionality to the LID-Monitor so it can also be used to manage bradykinesia.
Our consultant AI specialists, Michael Lones and Marta Vallejo, will be processing the data of machine learning establishers to make accurate and objective assessments of bradykinesia.